Table 1 Characteristics of 103 women with HER2/neu-overexpressing metastatic breast cancer

HER2/neu overexpression^a

Score 2+

31

30.1

Score 3+

72

69.9

Treatment

Single-agent trastuzumab

13

12.6

Trastuzumab + taxane

52

50.5

Trastuzumab + vinorelbine

11

10.7

Trastuzumab + taxane + megestrol acetate

6

5.8

Trastuzumab + taxane + tamoxifen

5

4.8

Trastuzumab + bevacizumab

5

4.8

Trastuzumab + taxane + carboplatin

4

3.9

Trastuzumab + taxane + CMF

3

2.9

Trastuzumab + erlotinib

2

1.9

Trastuzumab + doxorubicin + cyclophosphamide

2

1.9